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Abundant immunoglobulin (Ig)G4-positive plasma cells in interstitial pneumonia without
extrathoracic lesions of IgG4-related disease: is this finding specific to IgG4-related lung
disease?
Aims: There have been few reports on immunoglobu-
lin-G4 (IgG4)-related interstitial pneumonia (IP), and
its clinical features remain unclear. The objective of
this study was to assess whether IP with marked IgG4-
positive plasma cell infiltration without extrathoracic
lesions of IgG4-related disease (RD) should be diag-
nosed as a subtype of IgG4-RD or a separate entity.
Methods and results: All consecutive patients with
surgical lung biopsy-proven idiopathic IP with an
IgG4/IgG-positive cell ratio of >40% and >50 IgG4+
plasma cells in a high-power field without extratho-
racic lesions of IgG4-RD were reviewed retrospec-
tively. Five patients were enrolled into this study. All
patients were male with a history of smoking. Four
patients met the comprehensive diagnostic criteria for
IgG4-RD. The remaining patient lacked data related
to the serum IgG4 level. Histologically, a non-specific
IP pattern was observed in all patients. The key mor-
phological features of IgG4-RD, such as storiform
fibrosis and obliterative phlebitis with lymphoplasma-
cytic infiltration in a loose background texture, were
absent in every patient. In contrast, venule obstruc-
tion by densely packed lymphoplasmacytic infiltration
was observed in two patients. Marked scarring and
remodelling of the lung were also noted, which is not
seen typically in IgG4-RD. A favourable response to
corticosteroid monotherapy was observed in all
patients; however, two patients developed lung can-
cer during the course of observation.
Conclusions: IP with marked IgG4-positive plasma
cell infiltration without extrathoracic lesions of IgG4-
RD had different pathological features from those of
IgG4-RD, and it is appropriate to regard this as a sep-
arate entity.
Keywords: immunoglobulin G4-related disease, immunoglobulin G4-related lung disease, interstitial pneumonia,
lung cancer, obliterative phlebitis
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Introduction
Immunoglobulin G4-related disease (IgG4-RD) is a
recently recognized systemic fibro-inflammatory dis-
ease characterized by high serum IgG4 concentrations,
sclerosing inflammation with abundant IgG4-positive
plasma cells and good response to corticosteroid ther-
apy.1–5 The research committees for intractable pan-
creatic disease and intractable inflammatory bowel
disease, which are supported by the Ministry of Health,
Labour and Welfare of Japan, proposed the diagnostic
criteria for IgG4-RD in 2011.6 Based on the criteria,
IgG4-RD diagnosis is established when characteristic
diffuse/localized swelling or masses in single or multi-
ple organs, elevated serum IgG4 concentrations
(>135 mg/dl), marked lymphocyte and plasma cell
infiltration, fibrosis and IgG4+ plasma cell infiltration
[IgG4/IgG-positive cell ratio >40% and >10 IgG4+
plasma cells/high-power field (HPF)] are present. How-
ever, an elevation of local IgG4-positive cells or serum
IgG4 is not necessarily specific to IgG4-RD. Thus, a
definitive IgG4-RD diagnosis requires key morphologi-
cal features, such as storiform fibrosis and obliterative
phlebitis, to be present.
IgG4-related lung disease (IgG4-RLD) with intratho-
racic lesions is estimated to occur in 10% of IgG4-RD
cases and has been described previously as inflamma-
tory pseudotumour, interstitial pneumonia (IP),
mediastinal fibrosis, pleuritis and bronchial inflamma-
tion.7–12 To date, there have been a few reports on
IgG4-RLD.13–16 Further, there have been only a few
reports on IgG4-related IP, and its clinical features
remain unclear. Moreover, typical histological features
of IgG4-RD, such as storiform fibrosis and obliterative
phlebitis, have been observed rarely in the reported
IgG4-related IP cases. Thus, when the patients exhibit
IP with abundant IgG4-positive plasma cell infiltration
and have no extrathoracic lesions suggestive of IgG4-
RD, there is controversy concerning whether or not
they should be classified as IgG4-RLD.
In the present study, we reviewed retrospectively
consecutive patients with idiopathic IP with marked
IgG4-positive plasma cell infiltration without extratho-
racic lesions of IgG4-RD to assess whether this disease
should be diagnosed as a subtype of IgG4-RLD or
should be considered as a separate entity.
Methods
P A T I E N T S A N D S E T T I N G S
This retrospective study was conducted at Kana-
gawa Cardiovascular and Respiratory Center in
Yokohama city, Kanagawa, Japan. During January
2001–March 2013, surgical lung biopsies were per-
formed on 640 patients with diffuse lung disease.
Patients who had identifiable causes of interstitial
lung disease, such as exposure to occupational and
environmental agents (especially to inorganic or
organic dusts, drug-induced pulmonary toxicity and
radiation-induced pneumonitis) and complications of
connective tissue diseases (CTDs), were excluded
from this study. Patients who had extrathoracic
lesions of IgG4-RD were also excluded. Among 314
patients with idiopathic IP proven by surgical lung
biopsy, IgG and IgG4 immunostaining was per-
formed in 18 patients because of the presence of
numerous infiltrating plasma cells. Five patients with
an IgG4/IgG-positive cell ratio of >40% and >50
IgG4+ plasma cells in an HPF (according to the
consensus statement on the pathology of IgG4-RD
in the lung17) were enrolled and investigated in
terms of the clinical, radiological and pathological
features. Subsequently, we compared the character-
istics between these five patients and the remaining
13 patients with plasma cell-rich IP without abun-
dant IgG4+ plasma cell infiltration. The Ethics Com-
mittee of Kanagawa Cardiovascular and Respiratory
Center approved the study protocol. The Ethics
Committee approved the waiver of each patient’s
consent because it was a retrospective study with
high patient anonymity.
C L I N I C A L A N D L A B O R A T O R Y F I N D I N G S
Clinical and laboratory data used in the present
study were retrieved from patient medical records
and included gender, age, smoking history, comor-
bidities, symptoms and signs suggestive of CTD and
laboratory data [C-reactive protein (CRP), lactate
dehydrogenase, Krebs von den Lungen-6 (KL-6),
surfactant protein D, IgG, IgG4, IgE, interleukin
(IL)-6 and autoantibodies [anti-nucleolar antibody
(ANA), rheumatoid factor, anti-dsDNA antibody,
anti-Sj€ogren’s syndrome (anti-SS)-A antibody, anti-
SS-B antibody, anti-Jo-1 antibody, anti-topoisome-
rase 1 (Scl-70) antibody and anti-ribonucleoprotein
(RNP) antibody)].
R A D I O L O G I C A L F I N D I N G S
High-resolution computed tomography (HRCT) was
performed on all patients at the time of diagnosis.
The HRCT findings were reviewed and interpreted by
board-certified pulmonologists and radiologists
blinded to the biopsy results and clinical outcomes.
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The images were assessed for the dominant lung
zone, the dominant craniocaudal/axial distribution
and the dominant shadow [reticulation, ground-glass
opacity (GGO), or consolidation]. The presence of per-
ilymphatic interstitial thickening, traction bronchiec-
tasis, cysts, honeycombing and mediastinal/hilar
lymphadenopathy was also assessed. The HRCT pro-
tocol and the machine used were the same for all
patients studied. The radiologists determined the radi-
ological pattern of IP according to the HRCT criteria
for usual interstitial pneumonia (UIP) pattern in the
official American Thoracic Society (ATS)/European
Respiratory Society (ERS)/Japanese Respiratory Soci-
ety (JRS)/Latin American Thoracic Association
(ALAT) Statement: Idiopathic Pulmonary Fibrosis:
Evidence-Based Guidelines for Diagnosis and Manage-
ment.18 In 18 patients with plasma cell-rich IP whose
biopsy specimens were stained for IgG and IgG4, fol-
low-up CT was conducted at least every 6 months
during their clinical courses.
H I S T O P A T H O L O G I C A L F I N D I N G S
Formalin-fixed, paraffin-embedded surgical lung
biopsy specimens were stained with haematoxylin
and eosin and elastica van Gieson, with immunos-
taining for IgG and IgG4. Two pathologists reviewed
the specimens independently and determined the his-
tological patterns of IP according to the ATS/ERS
consensus classification for idiopathic IPs.19 The his-
tological specimens were also evaluated for the pres-
ence and distribution (pleura, alveolar wall,
interlobular septum, peribronchiolar, artery and vein)
of fibrosis, the presence and distribution of lympho-
plasmacytic infiltration, the presence of lymphoid fol-
licles, eosinophilic infiltration, the number of IgG4+
plasma cells/HPF, IgG4/IgG-positive cell ratio and
venous and/or arterial obstruction. The pathologist
counted in three fields with the highest numbers of
IgG+ and IgG4+ plasma cells and then calculated the
mean numbers and IgG4/IgG-positive cell ratio.
Results
P A T I E N T C H A R A C T E R I S T I C S
The patients’ characteristics are described in Table 1.
All five patients were male with a history of smoking.
The median age at the time of surgical lung biopsy
was 72 years, and cough was the most frequent
symptom on presentation. The serum KL-6 levels
were relatively high, with a median of 1800 U/ml
(reference values: >500 U/ml). The median serum
IgG4 level was 337.5 mg/dl, median IgE level was
417 IU/ml and median IgG4/IgG ratio was 18.9%.
ANA were positive in four patients (all patients had
homogeneous patterns, and two patients were also
positive for speckled pattern). Although one patient
was positive for anti-RNP antibody, symptoms/signs
or other autoantibodies specific to CTDs were not
detected. Angiotensin-converting enzyme and lyso-
zyme were negative in all patients. All patients
showed a slight increase in inflammatory reaction,
and the serum IL-6 levels were all within the normal
range. The median follow-up period was 48.1 months
(data cut-off date was 29 November 2015).
H R C T F I N D I N G S
The HRCT findings are shown in Table 2. GGO was
the most common (five patients), followed by reticular
shadow in four patients. Peribronchovascular distri-
bution was seen in two patients, whereas subpleural
distribution was present in another two patients. In
the remaining patient, both distributions were
observed. All findings were observed bilaterally and
predominantly in the lower lobes. According to the
HRCT criteria for UIP patterns in the official ATS/
ERS/JRS/ALAT statement,18 all patients were classi-
fied as being inconsistent with the UIP pattern. Cases
4 and 5 were diagnosed with a non-specific intersti-
tial pneumonia (NSIP) pattern. Case 3 was observed
as having thickening of the bronchovascular bundle
and interlobular septa; thus, it was difficult to deter-
mine whether this patient had NSIP pattern or some
kind of lymphoproliferative disease. Thickening of the
bronchovascular bundles and interlobular septa was
observed in three patients. Mediastinal/hilar lym-
phadenopathy was observed in all patients. No clear
nodular shadows were observed in the HRCT find-
ings, at least during the initial examination.
H I S T O P A T H O L O G I C A L F I N D I N G S
The histopathological findings are summarized in
Table 3. In four patients, tissues were obtained from
two different locations, one from the upper or middle
lobe and the other from the lower lobe. In the
remaining patient, a biopsy sample was obtained
from the lower lobe only.
In all patients, dense lymphoplasmacytic infiltration,
including numerous plasma cells, was noted in the
alveolar wall, peribronchiolar regions, interlobular
septa and pleura. Eosinophils were seen occasionally in
three patients, but their numbers were low (maximum
one cell/HPF). Lymphoid follicles with a germinal
© 2016 John Wiley & Sons Ltd, Histopathology
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centre were observed in all patients. Granulomatous
inflammation and neutrophilic infiltration were absent.
There were no characteristic findings of multicentric
Castleman’s disease, such as small and atrophic
germinal centres of the lymph nodes and hyalinization
of the blood vessels. In addition, anti-j staining and
anti-k staining were performed for all patients, and
absence of monoclonality was confirmed.
With regard to the IP pattern, in cases 2, 4 and 5,
fibrosis was associated with the inflammatory cell infil-
tration, and even foci of fibrous obliteration (scarring)
of pre-existing pulmonary parenchyma with or with-
out inflammatory cells were seen, suggesting a diagno-
sis of fibrosing NSIP (f-NSIP) (Figure 1). In case 3, the
organizing pneumonia pattern, in which polypoid con-
nective tissues with plump fibroblasts and surrounding
myxoid matrix plugged the alveolar spaces, was also
remarkable, but fibrosis was not evident, suggesting a
diagnosis of cellular NSIP. In case 1, a heterogeneous
appearance with alternating areas of normal lung and
dense fibrosis was also observed, thus suggesting
unclassifiable IP (UIP + f-NSIP pattern). The scarring
was particularly evident in case 2 and resulted in air
space enlargement or honeycombing, which made it
difficult to distinguish it from the UIP pattern. Regard-
ing smoking-related changes, emphysema was
observed in all five patients, and a desquamative IP-
like reaction was also noted focally in two patients.
The median number of IgG4-positive cells was 61/
HPF, and the median IgG4/IgG-positive cell ratio was
75% (Figure 1). Storiform fibrosis, a typical histologi-
cal appearance of IgG4-RD, was absent in all patients.
Obstruction of arteries and veins by densely packed
lymphoplasmacytic infiltration was observed in cases
1 and 3 (Figure 2).
T R E A T M E N T A N D O U T C O M E S
All five patients were treated with prednisolone
0.5–0.6 mg/kg/day, resulting in rapid improvements
in the serum IgG4 levels and image findings (Figure 3).
Cyclosporin was used concomitantly in two patients
Table 1. Patient characteristics
Case 1 Case 2 Case 3 Case 4 Case 5
Gender Male Male Male Male Male
Age (years) 72 55 73 71 78
Smoking history
status Current Current Past Past Past
pack-years 52 26.3 48 45 40
Comorbidities Cataract HT Duodenal ulcer HT, HL, CKD HL, gout
BPH, AAA cholelithiasis colon polyp
Laboratory data
CRP (mg/dl) 0.7 0.46 0.55 0.05 0.59
LDH (IU/l) 134 258 248 233 317
KL-6 (U/ml) 403 3685 772 1800 2161
SP-D (ng/dl) 173 604 70.4 74.5 462
IgG4 (mg/dl) Unmeasured 380 1070 223 295
IgG4/IgG (%) – 18 27.1 19.8 11.1
IgE (IU/ml) 250 ND 417 ND 873
IL-6 (pg/ml) Unmeasured ND < 8 < 8 < 8
Antiperinucleolar antibody 640 640 640 < 40 1280
Other autoantibody – Anti-RNP – – –
CRP, C-reactive protein; Ig, Immunoglobulin; IL-6, Interleukin-6; KL-6, Krebs von den Lungen-6; LDH, lactate dehydrogenase; SP-D, surfac-
tant protein; ND, not determined.
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but was stopped eventually in both patients because of
the rapid response to prednisolone and concerns over
immunosuppressant side effects. Prednisolone dose was
decreased gradually in all patients. In two patients, the
disease relapsed at a dose of 5–10 mg and improved
only after re-escalation of the prednisolone dose.
Two patients developed lung cancer during their
clinical courses (Figure 4): one patient was diagnosed
with small-cell lung carcinoma (case 1) and the other
patient with adenocarcinoma (case 2). The disease
stage at the time of diagnosis was cT4N3M0 stage
IIIB for small-cell lung carcinoma, and the patient
with adenocarcinoma was diagnosed with advanced
lung cancer at cT4N3M1b stage IV. The time
between the diagnosis of IP and lung cancer was
57.5 months in case 1 and 14.5 months in case 2.
C O M P A R I S O N O F P L A S M A C E L L - R I C H I P P A T I E N T S
W I T H A N D W I T H O U T A B U N D A N T I G G 4 - P O S I T I V E
P L A S M A C E L L I N F I L T R A T I O N
Regarding 18 patients with idiopathic IP with lym-
phoplasmacytic infiltration whose biopsy specimens
were stained for IgG and IgG4 in our hospital, we
compared the characteristics between a group of five
patients with an IgG4/IgG-positive cell ratio of >40%
and >50 IgG4+ plasma cells in a HPF (IgG4-positive
group) and another group of 13 patients (IgG4-nega-
tive group) (Table 4). The ratio of female patients
was significantly higher in the IgG4-negative group
than in the IgG4-positive group (P = 0.0290). The
serum level of IgG4 was significantly higher in the
IgG4-positive group (P = 0.00559). Histopathologi-
cally, f-NSIP pattern and lymphoid follicles with a
germinal centre were often observed in both groups.
In the IgG4-positive group, cyclosporin was used con-
comitantly in two patients (40%) but could eventu-
ally be stopped. In contrast, seven of 13 patients
(53.8%) needed concomitant therapy with cyclos-
porin, and five of 13 patients (38.5%) needed con-
comitant therapy with cyclophosphamide in the
IgG4-negative group. The incidence of lung cancer
was higher in the IgG4-positive group than in the
IgG4-negative group, although this difference did not
reach statistical significance (P = 0.172). In the
IgG4-positive group, no patients developed CTD
Table 2. HRCT findings
Case 1 Case 2 Case 3 Case 4 Case 5
Radiological diagnosis Inconsistent with UIP Inconsistent with UIP NSIP or LPD NSIP NSIP
Predominant lung zone Lower Lower Lower Lower Lower
Distribution
subpleural + + +  
Peri-bronchovascular   + + +
Shadow
Ground glass opacity + + + + +
Reticular shadow + +  + +
Consolidation   +  
Thickening of peri-lymphatic interstitium
Bronchovascular bundles   + + +
Interlobular septa   + + +
Traction bronchiectasis + +   
Cyst + +  + 
Honeycombing + +   
Mediastinal/hilar lymphadenopathy + + + + +
HRCT, High-resolution computed tomography; LPD, Lymphoproliferative disease; NSIP, Non-specific interstitial pneumonia; UIP, Usual
interstitial pneumonia.
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during their clinical courses, although two of 13
patients (15.4%) developed CTD (rheumatoid arthritis
and Sj€ogren’s syndrome) in the IgG4-negative group.
Discussion
In this work, we studied five patients with IP with
marked IgG4-positive plasma cell infiltration without
extrathoracic lesions of IgG4-RD. Four patients met
the comprehensive diagnostic criteria for IgG4-RD.6
The remaining patient lacked data related to the
serum IgG4 level, but the serum IgG level was found
to be markedly high (3910 mg/dl), and it was proba-
bly thought that the serum IgG4 was ≥135. How-
ever, we hesitate to conclude that the five patients
presented here represent IgG4-RLD cases, because
their histopathological findings differed from those of
previously reported IgG4-RD cases in terms of the
following points: (i) absence of storiform fibrosis,
(ii) marked scarring and remodelling of the lung and
(iii) obstruction of arteries and veins by densely
packed lymphoplasmacytic infiltration.
Storiform fibrosis is a key morphological feature
of IgG4-RD, which appears to be the same in
Table 3. Pathological findings
Biopsy site
Case 1 Case 2 Case 3 Case 4 Case 5
RT.S5 Rt.S9 Rt.S9 Lt.S1+2 Lt.S9 Lt.S5 Lt.S9 Rt.S2 Rt.S8-9
Histological pattern f-NSIP Unclassified f-NSIP or probable UIP c-NSIP c-NSIP Emphysema f-NSIP f-NSIP f-NSIP
Fibrosis
Pleura + +  +  + + + +
Alveolar wall + + + + +  + + +
Interlobular septum + + +  +  + + +
Peribronchiolar  +     +  
Artery  +     + + +
Vein + +     + + +
Lymphoplasmacyte infiltration
Pleura + + + + + + + + +
Alveolar wall + + + + +  + + +
Interlobular septum + +  + + + + + +
Peribronchiolar  + + + + + + + 
Artery  +  + + + + + 
Vein + +   + + + + +
Obstruction of vessels
Artery  +  +     
Vein + +   +    
Lymphoid follicle + + + + + + + + +
Eosinophil infiltration +   +     +
IgG4+ plasma cell/HPF (mean) 118 52.3 182 61.0 51.7
IgG4/IgG ratio (mean) 75% 78% 106% 56% 43%
c-NSIP, Cellular non-specific interstitial pneumonia; f-NSIP: Fibrosing non-specific interstitial pneumonia; HPF: High-power field; Ig:
Immunoglobulin.
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IgG4-RLD cases with multiple organ lesions.14 How-
ever, in the present study storiform fibrosis was not
observed in any patients. Further, marked scarring
and remodelling of the lung were observed (Fig-
ure 5), which are not seen typically in lesions of
typical IgG4-RD. Moreover, with regard to the oblit-
erative phlebitis observed in cases 1 and 3, venules
were occluded simply by infiltrating lymphocytes,
which is not entirely specific to IgG4-RD. According
to Miyabe,20 the diagnostic obliterative phlebitis seen
in type 1 autoimmune pancreatitis (AIP; also called
IgG4-related pancreatitis) revealed lymphoplasma-
cytic infiltration in a loose background texture,
which resembles the histological features found in
other areas of inflamed pancreas. In contrast, simple
venule obliteration by fibrosis or lymphocytic infiltra-
tion is also observed in chronic pancreatitis and
pancreatic adenocarcinoma. These pathological/
morphological differences imply that our patients
should not be diagnosed simply as a subtype of
IgG4-RLD.
In contrast, findings such as abundant lymphoid
follicles with a germinal centre and lymphoplasma-
cytic infiltration in perilymphatic lesions in our
patients are suggestive of CTD-related IP. All five
patients showed NSIP and/or UIP determined by sur-
gical lung biopsy specimen, insufficient extrathoracic
features of definite CTDs, no identifiable aetiology for
IP and histopathological features such as lymphoid
follicle with germinal centres and prominent plasma-
cytic infiltration. In addition, cases 1, 2, 3 and 5 also
showed strong positive results for antinuclear anti-
body; thereby, all five patients met the diagnostic
criteria for lung-dominant CTD proposed by Fisher.21
CTD is a frequent cause of NSIP, and a substantial
percentage of patients with idiopathic NSIP have
Figure 1. Microscopic
examination. Representative
photographs from the
microscopic examination are
presented. Case 1 [A,
haematoxylin and eosin (HE)
stain] presented fibrosis
associated with inflammatory
cell infiltration in the alveolar
wall, peribronchiolar regions,
interlobular septa and pleura,
suggesting the diagnosis of
fibrosing non-specific
interstitial pneumonia (NSIP).
In case 1, immunostaining of
CD138 (B), immunoglobulin
(Ig)G (C) and IgG4 (D) showed
abundant IgG4+ plasma cell
infiltration (IgG4/IgG-positive
cell ratio of 75% and 118
IgG4+ plasma cells/high-power
field).
Figure 2. Obliterative phlebitis.
Representative photographs of
obliterative phlebitis are
presented. In case 3, vein
obstruction by densely packed
lymphoplasmacytic infiltration
was observed [A: haematoxylin
and eosin (H&E) stain; B,
elastica van Gieson (EVG)
stain].
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some findings which were suggestive of, but were not
diagnostic for, a specific CTD. However, if these
patients have unidentified CTD it seems highly coinci-
dental that all the patients studied are male, because
CTD is found predominantly in females.22 In addition,
to date, none of the patients with IgG4-positive IP
developed symptoms and signs suggestive of a specific
CTD. Moreover, although our patients showed favour-
able responses to corticosteroid monotherapy, most
patients with CTD-associated NSIP, such as dermato-
myositis and scleroderma, need concomitant
immunosuppressant therapy.23,24 With regard to
Sj€ogren’s syndrome (SjS), clinically significant IP is
rare, and most SjS-IP patients exhibit a mild and self-
limiting disease course.25 For these reasons, our
patients may also be different from those with typical
CTD-related IP.
Conversely, among 13 patients who presented plasma
cell-rich IP without abundant IgG4-positive plasma cells
infiltration in our hospital, 11 patients (84.6%) also met
the diagnostic criteria for lung-dominant CTD. Unlike
the IgG4-positive group, these patients had the following
three features suggestive of typical CTD-related IP: (i)
the ratio of female patients was high, (ii) many patients
need concomitant cyclosporin and/or cyclophosphamide
for a long period and (iii) two patients (15.4%) devel-
oped CTD during clinical course. Thus, among the
patients with IP with lymphoplasmacytic infiltration,
which has been considered conventionally as lung-
dominant CTD, it may be better to discriminate between
IgG4-positive and IgG4-negative groups.
Meanwhile, the high incidence of lung cancer (40%)
during the course of treatment is a major concern. In
the present study, no clear mass shadows were
Case 1 Case 2 Case 3 Case 4 Case 5
Figure 3. Chronological changes in radiological findings. Chronological changes in computed tomography (CT) findings before and after
treatment initiation. In all cases, rapid improvements were observed.
Figure 4. Occurrence of lung
cancer. Two cases developed
lung cancer during the course
of observation: case 1 with
small-cell lung carcinoma (A)
and case 2 with
adenocarcinoma (B). No clear
nodular shadows were
observed in the computed
tomography (CT) findings, at
least during the initial
examination.
© 2016 John Wiley & Sons Ltd, Histopathology
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observed in the CT findings, at least during the initial
examination, and follow-up CT was conducted at least
every 6 months. In a report by Yamamoto,26 malig-
nancy complication rates in patients with IgG4-RD
was 10.4%, and the standardized incidence ratio for
malignancies in IgG4-RD was 383.0, which is sub-
stantially higher than that for the general population.
Recently, regulatory T cells have been demonstrated to
play a role in IgG4-RD pathogenesis.27 Regulatory T
cells may suppress not only the usual inflammation
but also tumour immunity.28 Moreover, in pancreatic
cancer, IgG4+ plasma cell infiltration was reportedly
observed in the normal pancreatic tissues surrounding
cancers, and some patients showed elevated serum
IgG4 levels.29 Shiokawa reported that the highest risk
for cancer in the first year after AIP diagnosis and the
absence of AIP relapse after successful treatment of
the coexisting cancers suggests that AIP may develop
Table 4. Comparison of plasma cell-rich IP patients with and without abundant IgG4-positive plasma cells infiltration
　 IgG4-positive group (n = 5) IgG4-negative group (n = 13) P-value
Characteristics
Age 72.0 (55.0–78.0) 64.0 (56.0–73.0) 0.152
Gender (male/female) 5/0 4/9 0.0290
Current/ex-/never smoker 2/3/0 0/6/7 –
Laboratory data
IgG 2647 (1126–3943) 1953 (1020–2937) 0.328
IgG4 338 (223–1070) 111 (8.00–235) 0.00559
IgE 417 (250–873) 735 (306–8521) 0.393
Antinucleolar antibody (%) 4 (80.0%) 5 (38.5%) 0.294
Pathological findings
f-NSIP/c-NSIP/UIP 4/1/0 8/1/4 –
DIP-like reaction (%) 2 (40.0%) 1 (7.7%) 0.172
Storiform fibrosis (%) 0 0 NA
Obstruction of artery/vein (%) 2 (40.0%) 0 0.0650
Lymphoid follicle (%) 5 (100%) 11 (84.6%) 1.00
Treatment
Corticosteroid (%) 5 (100%) 9 (69.2%) 0.278
Cyclosporin 2* (40.0%) 7 (53.8%) 1.00
Cyclophosphamide 0 5 (38.5%) 0.249
Outcome
Lung cancer (%) 2 (40.0%) 1 (7.7%) 0.172
Connective tissue disease (%) 0 2 (15.4%, RA and SjS) 1.00
Death (%) 2 (40.0%) 5 (38.5%) 1.00
Ig, Immunoglobulin; NSIP, Non-specific interstitial pneumonia; UIP, Usual interstitial pneumonia; DIP, Desquamative interstitial pneumonia;
RA, Rheumatoid arthritis; SjS, Sj€ogren’s syndrome; NA, not available.
Categorical data are presented as numbers (percentages) and were analysed using Fisher’s exact test. Continuous data are presented as
medians (interquartile ranges) and were analysed using the Mann–Whitney U-test. A P-value of < 0.05 was considered statistically signifi-
cant.
*In the IgG4-positive group, cyclosporin was used concomitantly in two patients but was eventually stopped in both patients because of
the rapid response to prednisolone and concerns over immunosuppressant side effects.
© 2016 John Wiley & Sons Ltd, Histopathology
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as a paraneoplastic syndrome in some.30 It is possible
that IgG4-positive plasma cells increase in number in
the tissues as a result of some allergic reaction or anti-
inflammatory reaction around the lung cancer, or
para-neoplastic syndrome. However, the number of
patients in this series was very low (n = 5), and
thereby further investigation is required regarding
whether lung cancer incidence is actually high in the
observed group of disorders or whether it is related to
smoking or interstitial pneumonia.
As described above, there are clear differences in
the pathological features between our patients and
those with typical IgG4-RD. Therefore, we believe
that it is appropriate to regard IP with marked IgG4-
positive plasma cell infiltration without extrathoracic
lesions of IgG4-RD as a separate entity. Moreover, a
favourable response to corticosteroid monotherapy
and a high frequency of lung carcinoma were note-
worthy and, thus, IgG and IgG4 immunostaining
should be performed more consistently to discriminate
such patients from those with idiopathic IP with lym-
phoplasmacytic infiltration.
A limitation of the present study is the retrospec-
tive, single-centre study design. Further, the number
of enrolled patients was low and there was no clear
practice standard of IgG and IgG4 immunostaining;
thus, we subjectively chose IP patients with numer-
ous infiltrating plasma cells. In future, there is a need
to accumulate more cases and compare the patients
with those with IP of various aetiologies after per-
forming IgG/IgG4 immunostaining.
Conclusions
IP with marked IgG4-positive plasma cell infiltration
without extrathoracic lesions of IgG4-RD had clearly
different pathological features from IgG4-RLD; thus, it
is appropriate to regard it as a separate entity. More
cases need to be accumulated, and further investiga-
tions should be conducted in future.
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Low body surface area predicts 
hepatotoxicity of nintedanib in 
patients with idiopathic pulmonary 
fibrosis
Satoshi Ikeda  1,2, Akimasa Sekine1, Tomohisa Baba1, Yumie Yamanaka1, Shinko Sadoyama1, 
Hideaki Yamakawa1, Tsuneyuki Oda1, Ryo Okuda1, Hideya Kitamura1, Koji Okudela2, Tae 
Iwasawa3, Kenichi Ohashi2, Tamiko Takemura4 & Takashi Ogura1
After the commercialization of nintedanib in Japan, a high incidence of hepatotoxicity resulting 
in treatment interruption was noted in idiopathic pulmonary fibrosis (IPF) patients treated with 
nintedanib in our hospital. This study aimed to clarify the risk factors for hepatotoxicity of nintedanib. 
Sixty-eight consecutive cases of IPF newly treated with nintedanib at a dose of 150 mg twice daily 
from September 2015 to September 2016 were enrolled: 46 patients (67.6%) exhibited aspartate 
aminotransferase (AST) and/or alanine aminotransferase (ALT) elevation and 16 patients (23.5%) also 
had a Common Terminology Criteria for Adverse Events (CTCAE) grade ≥2. Body surface area (BSA) 
was significantly lower in the CTCAE grade ≥2 group than in another group. A multivariate logistic 
regression analysis showed that the association between BSA and AST/ALT elevation with CTCAE grade 
≥2 was statistically significant. Eight of 10 patients who resumed nintedanib at a reduced dose of 
100 mg twice daily after interruption due to hepatotoxicity did not again develop AST/ALT elevation. In 
conclusion, a low BSA was associated with hepatotoxicity of nintedanib at a dose of 150 mg twice daily. 
It would be a good option for patients with a small physique to start nintedanib at a dose of 100 mg 
twice daily and then increase if possible after confirming its safety.
Nintedanib is a small-molecule tyrosine kinase inhibitor that inhibits vascular endothelial growth factor, 
platelet-derived growth factor, and fibroblast growth factor1, 2. Two randomized phase III trials (INPULSIS™-1 
and -2) showed that nintedanib reduced the decline in forced vital capacity (FVC) in patients with idiopathic 
pulmonary fibrosis (IPF) with a manageable side effect profile3–5. Based on these trial results, nintedanib was 
approved for IPF by the Pharmaceutical and Medical Devices Agency in Japan and was clinically deployed from 
September 2015.
However, after the commercialization of nintedanib for IPF, a high incidence of hepatotoxicity resulting in 
treatment interruption was noted in our hospital. We previously reported that 11 of 32 patients with IPF newly 
treated with nintedanib at a dose of 150 mg twice daily from September to December 2015 exhibited aspar-
tate aminotransferase (AST) and/or alanine aminotransferase (ALT) elevation with the Common Terminology 
Criteria for Adverse Events (CTCAE) grade ≥26, 7. In addition, this study showed that body mass index (BMI) 
and body surface area (BSA) were significantly lower in patients who presented with hepatotoxicity, and that 
hepatotoxicity was more frequent when BSA was <1.50 m2 and BMI was <22.
In the present study, we accumulated more cases and conducted further investigations to clarify the risk fac-
tors for hepatotoxicity of nintedanib in patients with IPF.
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Results
Characteristics. Patient characteristics are summarized in Table 1. Sixty-eight patients with IPF were 
enrolled in this study of which 76.5% were male with a median age of 72 years. The median body weight, BMI, 
and BSA estimated using the Du Bois formula were 57.7 kg, 22.1, and 1.64 m2, respectively. The median % FVC 
and % diffusing capacity for lung carbon monoxide (DLCO) at baseline were 62.3% and 50.8%, respectively. The 
most common concomitant drug was prednisolone (16.2%) followed by tacrolimus (7.4%). The median follow up 
period was 235 days (data cut-off date was October 19, 2016).
Hepatotoxicity of nintedanib. Adverse events in terms of hepatotoxicity are summarized in Table 2. A 
high proportion of patients had elevated levels of liver enzymes: 46 patients (67.6%) exhibited AST and/or ALT 
elevation and 16 patients (23.5%) were CTCAE grade ≥2 with a median interval of 6 days. Three patients expe-
rienced acute hypochondriac pain before AST and/or ALT elevation with a CTCAE grade ≥2 were detected. An 
elevation in γ-GTP was also frequently observed and CTCAE grade ≥2 appeared in 40 patients (58.8%).
Comparison of characteristics and examination findings with and without hepatotoxicity. A 
comparison between a group of 16 patients who demonstrated AST and/or ALT elevation with a CTCAE grade 
≥2 and another group of 52 patients is shown in Table 3. The BSA was significantly lower in the CTCAE grade 
≥2 group than in the CTCAE grade <2 group (p = 0.0484). Body weight was also lower in CTCAE grade ≥2 
group, although this difference did not reach statistical significance (p = 0.0765). No significant differences were 
observed in terms of age, gender, laboratory data at the first visit, pulmonary function tests, six minute walk test, 
and concomitant therapy between the 2 groups.
Risk factors for hepatotoxicity of nintedanib. We evaluated the risk factors for AST and/or ALT eleva-
tion with a CTCAE grade ≥2 (Table 4). Referring to the results of comparison with and without hepatotoxicity, 
Our patients
Nintedanib group in 
INPULSIS trials
Japanese Overall
Number of patients 68 76 638
Age 72.0 (68.0–76.0) 68.4 ± 7.6* 66.6 ± 8.1*
Gender (male/female) 52/16 62/14 507/131
Physique
    Height (cm) 164 (158–169) — —
    Body weight (kg) 57.7 (51.2–69.8) 63.8 ± 11.6* 79.2 ± 16.6*
    Body mass index 22.1 (19.6–25.0) 24.4 ± 3.4* 28.1 ± 4.6*
    Body surface area (DuBois, m2) 1.64 (1.48–1.79) — —
Laboratory data
    Aspartate aminotransferase (IU/L) 21.0 (17.8–24.5) — —
    Alanine aminotransferase (IU/L) 14.0 (11.0–22.0) — —
    Alkaline phosphatase (IU/L) 241 (194–283) — —
    Total bilirubin (mg/dL) 0.50 (0.40–0.62) — —
    γ-glutamyl transpeptidase (IU/L) 28.0 (20.0–52.8) — —
    Creatinine (mg/dL) 0.82 (0.69–0.92) — —
    Krebs von den Lungen-6 (U/mL) 1067 (694–1560) — —
    Surfactant protein D (ng/dL) 294 (182–409) — —
Pulmonary function test
    forced vital capacity (L) 1.90 (1.41–2.35) 2.42 ± 0.67* 2.71 ± 0.76*
    % forced vital capacity (%) 62.3 (50.1–72.1) 80.9 ± 16.6* 79.7 ± 17.6*
    % DLCO (%) 50.8 (41.3–63.6) 44.6 ± 11.4* 47.4 ± 13.5*
Six minute walk test
    lowest SpO2 (%) 82.0 (76.0–87.0) — —
    walking distance (meter) 410 (340–480) — —
Concomitant therapy
    Prednisolone (%) 11 (16.2%) 9 (11.8%) 136 (21.3%)
    Cyclosporine (%) 2 (2.9%) 0 0
    Cyclophosphamide (%) 2 (2.9%) 0 0
    Tacrolimus (%) 5 (7.4%) 0 0
    Pirfenidone (%) 2 (2.9%) 0 0
Table 1. Patient characteristics. Categorical data are presented as numbers (percentages) and continuous data 
are presented as medians (interquartile ranges). *Continuous data in INPULSIS trials are presented as the 
mean ± standard deviation. Abbreviations: DLCO = diffusing capacity for lung carbon monoxide.
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we selected BSA not only as the most possible candidate risk factor, but also as a representative factor related to 
physique. We also selected age, %FVC, %DLCO (these 3 factors had a significant impact on the assessment of 
severity and/or prognosis of IPF and have little relation with physique), and the baseline AST and ALT levels as 
candidate risk factors. A multivariate logistic regression analysis showed that the association between BSA and 
AST and/or ALT elevation with a CTCAE grade ≥2 was statistically significant (p = 0.0457).
A ROC curve analysis was used to determine the BSA cut-off values (Fig. 1). The area under the curve for 
BSA was 0.664 (95% confidence interval: 0.515–0.813) and the cut-off value for which sensitivity + specificity is 
maximal was 1.58 m2 (68.8% sensitivity and 65.4% specificity).
Treatment after interruption due to hepatotoxicity. Treatments after interruption due to hepato-
toxicity are summarized in Table 5. In 16 patients, treatment interruption was required due to AST and/or ALT 
elevation with a CTCAE grade ≥2. In all cases, hepatic enzyme elevations were completely reversible with treat-
ment interruption. Among 16 patients who needed a treatment interruption due to AST and/or ALT elevation 
with a CTCAE grade ≥2, re-administration at a reduced dose of 100 mg twice daily was performed in 10 patients. 
Treatment was successfully continued in 6 patients, whereas it was stopped in 4 patients due to the recurrence of 
AST and/or ALT elevation with a CTCAE grade ≥2 (2 patients) and nausea or fever (1 patient each). On the other 
hands, the remaining 6 patients who needed a treatment interruption due to AST and/or ALT elevation with a 
CTCAE grade ≥2 discontinued nintedanib treatment without resumption because of patient rejection or acute 
hypochondriac pain (2 patients each) and a deterioration in their physical condition or eosinophilia (1 patient 
each).
Discussion
The present study demonstrated the 3 following important clinical observations. First, a low BSA was associated 
with AST and/or ALT elevation with a CTCAE grade ≥2 when treated with nintedanib at a dose of 150 mg twice 
daily. Second, 80% of the patients who resumed nintedanib at a reduced dose of 100 mg twice daily after treat-
ment interruption due to hepatotoxicity did not again develop AST and/or ALT elevation with a CTCAE grade 
≥2. Third, 37.5% of the patients who needed treatment interruption due to hepatotoxicity could not resume 
nintedanib treatment.
To date, risk factors for hepatotoxicity of nintedanib in patients with IPF have not been fully investigated. 
However, the present study suggested that a low BSA predicts an AST and/or ALT elevation with a CTCAE 
grade ≥2 when treating with nintedanib at a dose of 150 mg twice daily. The incidence of hepatotoxicity in the 
present study was considerably higher than that reported in the INPULSIS trials (as shown in Table 2), whereas 
factors related to physique such as body weight, BMI, and absolute FVC values were considerably lower than 
those reported in the INPULSIS trials (Table 1)4. Similarly, a sub-analysis of the INPULSIS trials revealed that the 
incidence of AST and/or ALT elevation was higher in Japanese populations than in overall populations (Table 2), 
whereas body weight, BMI, and absolute FVC values were lower in Japanese patients than those in the overall 
population (Table 1)4, 5, 8, 9. Moreover, in a phase I study of nintedanib combined with docetaxel in Japanese 
patients with advanced non-small-cell lung cancer, the incidence of hepatotoxicity was higher in patients with 
a BSA < 1.50 m2 than in patients with a BSA ≥1.50 m2 10. These results indicate that physique is related to hepa-
totoxicity of nintedanib. Among the factors related to physique, BSA would be the most useful predictive factor.
CTCAE grading of the worst value
All grade ≥2 ≥3
Our patients (N = 68)
    AST elevation 44 (64.7%) 14 (20.6%) 6 (8.8%)
    ALT elevation 38 (55.9%) 12 (17.6%) 2 (2.9%)
    AST and/or ALT elevation 46 (67.6%) 16 (23.5%) 6 (8.8%)
    ALP elevation 29 (42.6%) 1 (1.5%) 0
    Total bilirubin elevation 5 (7.4%) 3 (4.4%) 2 (2.9%)
    γ-GTP elevation 40 (58.8%) 17 (25.0%) 2 (2.9%)
Nintedanib group in INPULSIS trials
Japanese patients (N = 76)
    AST elevation 26/72* (36.1%) 4 (5.3%) 2 (2.6%)
    ALT elevation 30/71* (42.3%) 4 (5.3%) 1 (1.3%)
    AST and/or ALT elevation — 5 (6.6%) 3 (3.9%)
  Overall population (N = 638)
    AST elevation 134/625* (21.4%) 21 (3.3%) 8 (1.3%)
    ALT elevation 169/620* (27.3%) 28 (4.4%) 10 (1.6%)
    AST and/or ALT elevation — 32 (5.0%) 14 (2.2%)
Table 2. Hepatotoxicity. Categorical data are presented as numbers (percentages). *The number of patients 
whose test results increased >the upper limit of the normal range/the number of patients whose test results 
were within the reference values at baseline. Abbreviations; AST = aspartate aminotransferase; ALT = alanine 
aminotransferase; ALP = alkaline phosphatase; T-Bil = total bilirubin; γ-GTP = γ-glutamyl transpeptidase; 
CTCAE = Common Terminology Criteria for Adverse Events.
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It is also noteworthy that 8 of 10 patients (80%) successfully resumed nintedanib at a reduced dose of 100 mg 
twice daily after treatment interruption due to AST and/or ALT elevation with a CTCAE grade ≥2 at a dose of 
150 mg twice daily. These 8 patients also had a small physique, with a median BSA of 1.57 m2. According to the 
pharmacokinetic analysis of nintedanib in Japanese patients, the area under the concentration-time curve and 
maximum concentration in plasma at a steady state were approximately two-times higher at a dose of 150 mg 
twice daily than those at a dose of 100 mg twice daily (39.7 ng/ml vs 20.0 ng/ml and 218 ng·h/ml vs 115 ng·h/
ml, respectively)11. These data suggested that hepatotoxicity would be associated with the plasma concentration 
of nintedanib. In the present study, it was speculated that the patients with a small build tended to have a high 
serum concentration at a dose of 150 mg twice daily, and thus, were more likely to develop AST and/or ALT 
elevation. However, as the bioavailability of nintedanib is relatively low, serum concentration of nintedanib may 
hepatotoxicity no hepatotoxicity p-value
Number of patients 16 52
Age 75.0 (68.8–76.3) 72.0 (68.0–76.0) 0.519
Gender (male/female) 11/5 41/11 0.502
Physique
    Height (cm) 160 (153–166) 164 (158–169) 0.188
    Body weight (kg) 53.2 (49.2–57.9) 62.0 (52.3–70.3) 0.0765
    Body mass index 21.5 (19.4–24.3) 22.4 (20.0–25.0) 0.311
    Body surface area (DuBois, m2) 1.52 (1.45–1.67) 1.67 (1.54–1.80) 0.0484
Laboratory data
    Aspartate aminotransferase (IU/L) 20.5 (16.5–31.5) 21.0 (18.0–24.0) 0.612
    Alanine aminotransferase (IU/L) 14.0 (11.0–29.0) 14.0 (11.0–20.3) 0.524
    Alkaline phosphatase (IU/L) 247 (211–280) 240 (189–283) 0.608
    Total bilirubin (mg/dL) 0.50 (0.40–0.62) 0.50 (0.40–0.62) 1.00
    γ-glutamyl transpeptidase (IU/L) 28.5 (21.5–63.8) 28.0 (20.0–48.0) 0.573
    Creatinine (mg/dL) 0.80 (0.68–0.90) 0.83 (0.70–0.92) 0.385
    Krebs von den Lungen-6 (U/mL) 920 (694–1356) 1080 (766–1592) 0.800
    Surfactant protein D (ng/dL) 262 (167–440) 309 (188–400) 0.691
Pulmonary function test
    forced vital capacity (L) 1.75 (1.37–2.42) 1.96 (1.65–2.34) 0.457
    %forced vital capacity (%) 64.0 (55.0–71.7) 60.9 (48.9–72.7) 0.822
    %DLCO (%) 51.4 (36.1–60.1) 50.4 (42.2–65.6) 0.464
Six-minute walk test
    lowest SpO2 (%) 81.5 (77.5–87.0) 82.0 (76.0–87.0) 0.922
    walking distance (meter) 378 (281–450) 430 (355–480) 0.299
Concomitant therapy
    Prednisolone (%) 3 (18.8%) 8 (15.4%) 0.712
    Cyclosporine (%) 0 2 (3.8%) 1.00
    Cyclophosphamide (%) 0 2 (3.8%) 1.00
    Tacrolimus (%) 1 (6.2%) 4 (7.7%) 1.00
    Pirfenidone (%) 1 (6.2%) 1 (1.9%) 0.418
Table 3. Comparison of characteristics and examination findings with and without hepatotoxicity. Categorical 
data are presented as numbers (percentages) while continuous data are presented as medians (interquartile 
ranges). Fisher’s exact test was used to compare categorical data and the Mann-Whitney U test was used to 
compare continuous data. Abbreviations: DLCO = diffusing capacity for lung carbon monoxide.
Odds 
ratio
95% confidence 
interval p-value
Body surface area 0.0208 0.000468–0.929 0.0457
Age 1.01 0.888–1.15 0.891
% forced vital capacity 0.988 0.947–1.03 0.564
% diffusing capacity for 
lung carbon monoxide 0.999 0.961–1.04 0.950
Baseline aspartate 
aminotransferase 1.09 0.950–1.25 0.224
Baseline alanine 
aminotransferase 1.00 0.932–1.08 0.994
Table 4. Multivariate logistic regression analysis.
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differ among individuals. Therefore, further pharmacokinetic analysis in various patients with different physiques 
is required.
In the present study, an AST and/or ALT elevation was completely reversible with a treatment interruption. 
However, 6 of the 16 patients (37.5%) who needed a treatment interruption due to AST and/or ALT elevation 
with a CTCAE grade ≥2 could not resume nintedanib treatment. It might have been unavoidable that those 
patients could not resume because of concerns over noteworthy side-effects such as eosinophilia in the peripheral 
blood and acute hypochondriac pain. However, at least another 3 patients were highly likely to have continued 
nintedanib treatment over a longer period if it were not for the interruption. In addition, recently, an interim anal-
ysis of the INPULSIS®-ON study showed that the beneficial effect of nintedanib on slowing disease progression 
was maintained and the change from baseline FVC was consistent over 2 or more years12. Thus, it is very impor-
tant to continue nintedanib treatment as long as possible without interruption and/or discontinuation by setting 
Figure 1. Receiver operating characteristic curve analysis. A receiver operating characteristic curve analysis 
was used to determine the cut-off values of body surface area. The area under the curve was 0.664 (95% 
confidence interval: 0.515–0.813) and the cut-off value for which sensitivity + specificity is maximal was 1.58 m2 
(68.8% sensitivity and 65.4% specificity).
n
Resume at a reduced dose of 100 mg twice daily 10
   Continue 6
   Re-interrupt 4
      recurrence of AST/ALT elevation with CTCAE grade ≥2 2
      nausea 1
      fever 1
Discontinue without resumption 6
      patient rejection 2
      acute hypochondriac pain 2
      deterioration of physical condition 1
      eosinophilia in peripheral blood 1
Table 5. Treatment after interruption due to AST and/or ALT elevation with a CTCAE grade ≥2. 
Abbreviations; AST = aspartate aminotransferase; ALT = alanine aminotransferase; CTCAE = Common 
Terminology Criteria for Adverse Events.
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the appropriate dosage for individual patients. For patients with a small physique, especially Japanese and eastern 
Asian patients with a BSA <1.58 m2, it would be a good option to start nintedanib at a dose of 100 mg twice daily 
and then increase the dose to 150 mg twice daily if possible after confirming its safety.
A limitation of the present study was the retrospective single-center study design. In addition, frequent blood 
sampling may provide an opportunity to detect a temporal AST and/or ALT elevation that may recover sponta-
neously. In the present study, the median interval from nintedanib initiation to AST and/or ALT elevation with 
a CTCAE grade ≥2 was only 6 days, whereas the protocol of the INPULSIS trials specified that hepatic enzymes 
must be examined once every 2 weeks during the first 6 weeks. The short observation period was also another 
limitation when assessing long-term safety.
In conclusion, a low BSA was associated with hepatotoxicity of nintedanib at a dose of 150 mg twice daily in 
patients with IPF. To continue nintedanib treatment as long as possible without interruption and/or discontinu-
ation, it would be a good option for patients with a small physique to start nintedanib at a dose of 100 mg twice 
daily and then increase the dose to 150 mg twice daily if possible after confirming its safety.
Methods
Patients and settings. This retrospective study was performed at the Kanagawa Cardiovascular and 
Respiratory Center in Yokohama City, Kanagawa, Japan. All consecutive cases of IPF newly treated with 
nintedanib at a dose of 150 mg twice daily from September 2015 to September 2016 were enrolled. The diagnosis 
of IPF was based on the official American Thoracic Society/European Respiratory Society/Japanese Respiratory 
Society/Latin American Thoracic Association statement of 201113. Patients with a previous history of nintedanib 
treatment (formerly known as BIBF1120) were excluded. This study has been carried out in accordance with the 
Declaration of Helsinki. The Ethics Committee of the Kanagawa Cardiovascular and Respiratory Center approved 
the study protocol (Approval date: November 30, 2016; Approved number: KCRC-16-0006) and patient consent 
was waived because this was a retrospective study and anonymity was secured.
Data availability. The datasets generated during and/or analysed during the current study are available from 
the corresponding author on reasonable request.
Clinical and laboratory findings. Clinical and laboratory data used in this study were retrieved from 
patient medical records and included age, gender, height, body weight, laboratory data [AST, ALT, alkaline 
phosphatase (ALP), total bilirubin (T-Bil), γ-glutamyl transpeptidase (γ-GTP), serum creatinine, Krebs von den 
Lungen-6 (KL-6), and surfactant protein D (SP-D)], pulmonary function tests, six minute walk test, and concom-
itant therapy. In all cases, hepatic enzymes were examined at least once within a week of nintedanib treatment 
initiation and at least once every 2–4 weeks thereafter.
Assessment and response for the hepatotoxicity. The worst examination values were graded using 
the CTCAE ver. 4.014. An elevation in AST and ALT was defined as follows: grade 1 was >3.0 × the upper limit 
of the normal range (ULN), grade 2 was >3.0–5.0 × ULN, grade 3 was >5.0–20.0 × ULN, and grade 4 was 
>20.0 × ULN. When a patient developed AST and/or ALT elevation with CTCAE grade ≥2, treatment inter-
ruption or dose reduction was needed in accordance with the guide for appropriate use of nintedanib (Ofev®)15.
Statistical analysis. Categorical data are presented as numbers (percentages) while continuous data are 
presented as medians (interquartile ranges). Fisher’s exact test was used to compare categorical data and the 
Mann-Whitney U test was used to compare continuous data. A multivariate logistic regression analysis was per-
formed to verify the risk of hepatotoxicity. A receiver operating characteristic (ROC) curve analysis was used to 
determine the optimal cut-off values for the risk factor; values with maximum joint sensitivity and specificity 
were selected. A p-value of <0.05 was considered statistically significant. All statistical analyses were performed 
with EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan)16, which is a graphical user interface 
for R Version 3.2.2 (The R Foundation for Statistical Computing, Vienna, Austria).
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Interstitial lung disease in clinically
amyopathic dermatomyositis with and
without anti-MDA-5 antibody: to lump or
split?
Satoshi Ikeda1* , Machiko Arita1, Mitsunori Morita1, Satoshi Ikeo1, Akihiro Ito1, Fumiaki Tokioka1, Maki Noyama1,
Kenta Misaki2, Kenji Notohara3 and Tadashi Ishida1
Abstract
Background: Interstitial lung disease (ILD) associated with clinically amyopathic dermatomyositis (CADM-ILD) is
often refractory and rapidly progressive. Although the anti-melanoma differentiation-associated gene 5 (anti-MDA-5)
antibody is associated with rapidly progressive ILD (RP-ILD), differences in clinical features and prognosis of anti-MDA-5
antibody-positive and -negative CADM-ILD remain unclear.
Methods: To clarify the differences in the clinical features and prognosis between anti-MDA-5 antibody-positive
and -negative cases, we retrospectively reviewed the medical records of patients diagnosed with CADM-ILD
with and without anti-MDA-5 antibody at Kurashiki Central Hospital from January 2005 to September 2014.
Results: Anti-MDA-5 antibody was found in 10 of 16 patients (63 %). The levels of Krebs von den Lungen-6 (KL-6)
and surfactant protein D (SP-D) at the first visit were significantly lower in positive patients than in negative patients,
whereas the levels of aspartate aminotransferase (AST), γ-glutamyl transpeptidase (γ-GTP), and the CD4+/CD8+ ratio in
the bronchoalveolar lavage (BAL) fluid were significantly higher in positive patients than negative patients. Subpleural
ground-glass opacity (GGO) or irregular linear opacity was predominant in positive patients. Peribronchovascular
consolidation was predominant in negative patients. Positive patients had significantly lower survival rates than
negative patients, with all six fatal cases occurring in positive patients who died of refractory ILD within 92 days
from the first visit despite intensive treatment.
Conclusions: There are clear differences in the clinical features and prognosis of anti-MDA-5 antibody-positive
and -negative CADM-ILD. Low serum KL-6 and SP-D levels, high serum AST and γ-GTP levels, high CD4+/CD8+ ratio in
BAL fluid, and predominance of subpleural GGO or irregular linear opacity in HRCT may help to discriminate anti-MDA-5
antibody-positive CADM-ILD with poor prognosis.
Keywords: Amyopathic dermatomyositis, Interstitial lung diseases, MDA-5 protein, human, Melanoma differentiation
associated protein-5, human
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Background
Interstitial lung disease (ILD) is the most common
internal organ manifestation that affects the prognosis of
clinically amyopathic dermatomyositis (CADM), as well as
polymyositis (PM) and dermatomyositis (DM). ILD associ-
ated with CADM (CADM-ILD) is often refractory and
rapidly progressive [1–3], resulting in respiratory failure
with a 6-month survival rate of 40.8–54.5 % [3–5].
Although no standard treatment regimen for CADM-ILD
has been established, intensive treatment with the three-
drug combination of corticosteroid, cyclosporine, and
cyclophosphamide is recommended in the early phase
even if respiratory symptoms are absent or mild [6, 7].
Among patients with CADM, anti-melanoma
differentiation-associated gene 5 (MDA-5) antibodies
are strongly associated with the development of
rapidly progressive ILD (RP-ILD) [8–10]. As MDA-5
plays the critical role in the innate immune defense
against viruses, one hypothesis is that the production of
anti–MDA-5 antibodies is a secondary phenomenon during
virus infection that is associated with the onset of CADM
and RP-ILD. However, to our knowledge, no previous study
has revealed whether the presence or absence of the anti-
MDA-5 antibody affects the clinical manifestation of
CADM-ILD.
In the present study, we retrospectively reviewed
consecutive cases of CADM-ILD to clarify the differences
in the clinical features and prognosis between anti-MDA-5
antibody-positive and -negative cases, and to determine
whether we should separate CADM-ILD by the presence
or absence of anti-MDA-5 antibody.
Methods
Patients and settings
This retrospective study was performed at Kurashiki central
hospital in Kurashiki city, Okayama, Japan. The patients
diagnosed with CADM-ILD at our hospital from January
2005 to September 2014 who had cryopreserved blood
serum before starting treatment were enrolled in this study.
Diagnoses of CADM were made by at least two pulmonol-
ogists and one rheumatologist based on the criteria of
Sontheimer [11]. In addition, patients who exhibited a rash
typical of DM without muscle weakness for less than
6 months and experienced fatal complications such as
acute/subacute ILD were also diagnosed with CADM ac-
cording to Gerami et al.’s criteria [12]. No exclusion criteria
were specified. The Ethics Committee of Kurashiki Central
Hospital approved the study protocol. The Ethics Commit-
tee approved the waiver of each patient’s consent because it
was a retrospective study and high anonymity was secured.
Identification of myositis-specific antibodies
Measurement of myositis-specific antibodies was carried
out by using cryopreserved blood serum before starting
treatment. Serum anti-MDA-5 antibody was measured by
immunoprecipitation using 35S-labeled HeLa cell extract
(Perkin Elmer, Waltham, MA, USA), which was confirmed
by enzyme-linked immunosorbent assay (SRL, Tokyo,
Japan). Other myositis-specific antibodies, including anti-
aminoacyl transfer RNA synthetase (anti-ARS) antibodies,
were measured using the Myositis Profile Euroline antibody
test system (EUROIMMUN, Lubeck, Germany), which
was confirmed by RNA immunoprecipitation (Bio-Rad
Laboratories, Hercules, CA, USA).
Clinical and laboratory findings
Clinical data and laboratory data used in the present study
were retrieved from patient medical records and included
gender, age, smoking history, length of time from onset of
symptoms to first visit, department of the first visit, symp-
toms and physical examination, laboratory data, and
results of bronchoalveolar lavage (BAL) and pulmonary
function tests. BAL was routinely performed under local
anesthesia before starting treatment. The bronchoscope
was wedged into the segmental bronchi. Only samples
with recovery >25 % were used. With regards to pulmon-
ary function test, forced vital capacity and diffusing
capacity for carbon monoxide were measured using same
machine and same method in all patients. Values were
expressed as a percentage of the predicted value.
Radiological findings
All patients underwent high-resolution computed
tomography (HRCT) at the time of diagnosis, and
HRCT findings were reviewed and interpreted by
board-certified pulmonologists and radiologists.
Images were assessed for the dominant craniocaudal/
axial distribution and the dominant shadow [consoli-
dation, ground-glass opacity (GGO), reticulation, or
irregular linear opacity]. The presence of traction
bronchiectasis, cyst, subpleural curve linear shadow,
thickening of the perilymphatic interstitium, emphy-
sema, and loss in lung volume were also assessed.
HRCT protocol and machine was the same for all
included patients at peak tube voltage of 120 kVp and
approximately ≤240 mAs using an automatic exposure
control system (Toshiba Medical Systems, Tochigi,
Japan).
Statistical analysis
Categorical data are presented as numbers (percentages),
while continuous data are presented as medians (inter-
quartile ranges). Fisher’s exact test was used to compare
categorical data, and the Mann–Whitney U test was
used to compare continuous data. Cumulative survival
probabilities were estimated using the Kaplan-Meier
method. The log-rank test was used to compare survival
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among patient groups. A p value of <0.05 was consid-
ered statistically significant.
Results
Characteristics
From January 2005 to September 2014, we encountered
18 cases of newly diagnosed ILD associated with CADM.
Anti-MDA-5 antibody was measured in 16 cases who had
cryopreserved blood serum before starting treatment.
Anti-MDA-5 antibody was present in 10 patients (positive
group) and absent in 6 patients (negative group). Patients’
characteristics are summarized in Table 1. The median
length of time from onset to first visit was shorter in the
positive group (15.5 vs. 51.0 days, respectively), although
the difference did not reach statistical significance
(p = 0.157). No significant differences were observed
in gender, age, smoking history, or symptoms and signs at
the time of diagnosis between the two groups.
Laboratory data
Laboratory data are summarized in Table 2. Aspartate
aminotransferase (AST) and γ-glutamyl transpeptidase
(γ-GTP) levels were significantly higher (p = 0.0225 and
0.00225, respectively) in the positive group when
compared to the negative group, whereas serum levels of
Krebs von den Lungen-6 (KL-6) and surfactant protein D
(SP-D) at the first visit were significantly lower (p = 0.0160
and 0.00402, respectively) in the positive group than in
the negative group. In the positive group, serum KL-6
gradually increased, whereas serum SP-D remained con-
sistently low 1–4 weeks after treatment initiation (Fig. 1).
In the negative group, one patient each was positive for
anti-Jo1 antibody, anti-PL-12 antibody, anti-OJ antibody,
and anti-PM/Scl-100 antibody. Regarding BAL fluid
analysis, the CD4+/CD8+ ratio was significantly higher in
the positive group than in the negative group (p = 0.0167).
HRCT findings
HRCT findings are shown in Table 3 and Fig. 2. In both
groups, there was a predominance of shadows in the lower
lobe. Subpleural distribution was predominant in the posi-
tive group, whereas peribronchovascular distribution was
predominant in the negative group. In the positive group,
GGO (50 %) was the most commonly observed shadow
followed by irregular linear opacity (30 %). Conversely, in
the negative group, the most common shadow was
consolidation with a significantly higher incidence than in
the positive group (p = 0.00762). While HRCT findings in
the positive and negative group often appeared to be mild,
most were associated with loss of lung volume (90 and
83 %, respectively) or traction bronchiectasis (50 and
67 %, respectively).
Treatments and outcomes
Three-drug combination therapy with corticosteroid, cyclo-
sporine, and cyclophosphamide was the most common
initial treatment in both groups (78 and 83 %, respectively).
The median follow-up period over both groups was
689 days (the data cutoff date was November 9, 2014). In
the present study, six deaths were observed during the
follow-up period; all six cases were positive for anti-MDA-5
antibody and died from refractory ILD within 92 days from
the first visit (median, 30.0 days). Five of these six cases
received intensive initial treatment with corticosteroid,
cyclosporine, and cyclophosphamide. The one remaining
case was refractory to the initial treatment with corticoster-
oid monotherapy, and thus subsequently received cyclo-
sporine and cyclophosphamide.
A comparison of survival curves is shown in Fig. 3.
The anti-MDA-5 antibody-positive group had significantly
lower survival rates than the negative group (p = 0.0252).
Comparison between survivors and non-survivors with
anti-MDA-5 antibody
A comparison between the survivors and non-survivors
in the positive group is shown in Table 4. The length of
time from onset to the first visit was shorter among the
non-survivors than the survivors, although this differ-
ence did not reach statistical significance (p = 0.0666).
Table 1 Summary of clinical characteristics
MDA-5 positive MDA-5 negative p value
(n = 10) (n = 6)
Gender (male/female) 6/4 2/4 0.608
Age 63.0 (58.0–64.8) 71.5 (64.8–73.8) 0.0913
Smoking history 5 (50 %) 2 (33 %) 0.633
Days from onset to first visit 15.5 (11.0–29.8) 51.0 (39.5–77.5) 0.157
Department of the first visit
Respiratory medicine 6 (60 %) 1 (17 %) –
Rheumatology 2 (20 %) 5 (83 %) –
Dermatology 2 (20 %) 0 –
Symptoms and signs at the time of diagnosis
Gottron’s sign/papule 7 (70 %) 5 (83 %) 1.00
Heliotrope eruption 7 (70 %) 1 (17 %) 0.119
V/shawl neck sign 5 (50 %) 2 (33 %) 0.633
Mechanic’s hands 2 (20 %) 2 (33 %) 0.604
Palmar erythema 2 (20 %) 1 (17 %) 1.00
Myalgia 3 (30 %) 0 0.250
Dry cough 5 (50 %) 4 (67 %) 0.633
Dyspnea on exertion 5 (50 %) 5 (83 %) 0.307
Fever 9 (90 %) 3 (50 %) 0.118
Categorical data are presented as numbers (percentages) and were analyzed using
Fisher’s exact test. Continuous data are presented as medians (interquartile ranges)
and were analyzed using the Mann–Whitney U test. A p value of <0.05 was
considered statistically significant
Abbreviation: MDA-5, anti-melanoma differentiation-associated gene 5
Ikeda et al. BMC Pulmonary Medicine  (2015) 15:159 Page 3 of 10
The length of time from onset to treatment initiation
was significantly shorter in non-survivors than in survivors
(p = 0.0381). As for the HRCT findings, the incidence of
GGO was significantly higher among non-survivors than
survivors (p = 0.0480). No significant differences were ob-
served in terms of gender, age, smoking history, PaO2/FiO2
ratio, or BAL fluid analysis results between the two groups.
Discussion
Previous studies, mainly from Asia, have demonstrated
that CADM-ILD often runs an aggressive course [3–5].
On the contrary, Cottin et al. reported good treatment
response and favorable prognosis of CADM-ILD in
France [13]. These results suggest that CADM-ILD in-
cludes a heterogeneous disease population. The present
study demonstrated the four following important clinical
observations. First, serum KL-6 and SP-D at the first
visit were significantly lower in the positive group than
in the negative group. Second, serum AST, γ- GTP, and
CD4+/CD8+ ratio in the BAL fluid were significantly
higher in the positive group than in the negative group.
Third, radiological findings were quite different between
the two groups. Fourth, anti-MDA-5 antibody-positive
cases had significantly lower survival rates than anti-
MDA-5 antibody-negative cases. These clinical differences
imply that anti-MDA-5 antibody-positive and -negative
CADM-ILD should be regarded as separate entities.
The biomarkers ILD, KL-6, and SP-D are reportedly
useful for assessing the prognosis of ILD in PM and DM
[14–16]. However, the usefulness of KL-6 and SP-D in
CADM-ILD has not been fully investigated in previous
research. In the present study, serum levels of KL-6 at
Table 2 Summary of the results of laboratory testing, bronchoalveolar lavage, and pulmonary function test
MDA-5 positive MDA-5 negative p value
(n = 10) (n = 6)
PaO2/FiO2 ratio 296 (274–359) 343 (332–357) 0.689
Laboratory data
White blood cell count (/μL) 5600 (4825–6300) 8150 (5775–10150) 0.573
Aspartate aminotransferase (IU/L) 55.5 (40.5–92.3) 28.5 (23.5–33.5) 0.0225
Alanine aminotransferase (IU/L) 27.0 (17.0–105) 17.0 (16.3–19.3) 0.252
γ-glutamyl transpeptidase (IU/L) 40.5 (23.0–60.5) 15.5 (14.0–22.3) 0.00225
Creatine phosphokinase (IU/L) 184 (90.3–467) 108 (85.8–268) 0.635
Aldolase (U/L) 6.15 (3.58–8.45) 7.50 (4.45–8.45) 0.713
C-reactive protein (mg/dL) 1.28 (0.90–2.94) 0.62 (0.36–3.53) 0.428
Lactate dehydrogenase (IU/L) 368 (302–390) 297 (259–331) 0.0925
Krebs von den Lungen-6 (U/mL) 600 (471–1072) 1700 (1027–3511) 0.0160
Surfactant protein D (ng/dL) 32.5 (22.8–47.6) 181 (98.1–378) 0.00402
Anti-ARS antibody 0 3 (50 %)
Anti Jo-1 0 1 (17 %)
Anti PL-12 0 1 (17 %)
Anti 0 J 0 1 (17 %)
Anti-PM/Scl-100 antibody 0 1 (17 %)
Bronchoalveolar lavage
Total cell count 300 (250–400) 500 (450–700) 0.131
Neutrophil (%) 3.00 (2.50–6.50) 11.0 (8.50–51.5) 0.0855
Eosinophil (%) 1.00 (0.00–1.00) 4.00 (2.00–5.50) 0.284
Lymphocyte (%) 30.0 (24.5–37.0) 41.0 (22.0–42.0) 0.819
Macrophage (%) 60.0 (59.5–70.5) 41.0 (23.0–44.0) 0.0396
CD4+/CD8+ ratio 1.68 (1.13–3.62) 0.420 (0.340–0.490) 0.0167
Lung function test
% Forced vital capacity 79.8 (67.4–90.4) 72.9 (53.4–93.6) 1.00
% Diffusing capacity for carbon monoxide 56.6 (50.2–63.7) 56.9 (54.7–63.0) 0.730
Categorical data are presented as numbers (percentages) and were analyzed using Fisher’s exact test. Continuous data are presented as medians (interquartile
ranges) and were analyzed using the Mann–Whitney U test. A p value of <0.05 was considered statistically significant
Abbreviation: MDA-5, anti-melanoma differentiation-associated gene 5
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the first visit were lower in the positive group than in
the negative group but gradually increased in most of
the cases during the observation period. Although the
cause is not clear, the two following reports may provide
clues for resolving this problem. First, Otsuka et al.
reported that in the early stage of acute exacerbation of
idiopathic pulmonary fibrosis, the elevation in serum
KL-6 mostly occurred after the manifestation of
symptoms and deterioration of HRCT findings and the
other biomarkers of ILD [17]. Second, Sakamoto et al.
reported that the serum levels of KL-6 are significantly
correlated with the extent of traction bronchiectasis
observed in HRCT, which is an indicator of the patho-
logic grade of fibrosis [18]. As anti-MDA-5 antibody-
positive cases tend to progress more rapidly compared
with anti-MDA-5 antibody-negative cases, serum KL-6
Fig. 1 Chronological changes in serum KL-6 and SP-D. a Serum KL-6 levels at first visit and after 1–4 weeks’ treatment initiation in each patient of
the anti-MDA-5 antibody positive (left) and negative groups (right). b Serum SP-D levels at first visit and after 1–4 weeks’ treatment initiation in each
patient of the anti-MDA-5 antibody positive (left) and negative groups (right). Abbreviations: KL-6, Krebs von den Lungen-6; SP-D, surfactant protein D;
MDA-5, anti-melanoma differentiation-associated gene 5
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levels may not yet have increased in anti-MDA-5 antibody-
positive cases at the first medical examination. However,
the higher values of KL-6 in the negative group might be
somewhat affected by 2 subjects who have especially high
KL-6 at first visit, thus we must be careful in interpreting
the results. On the other hand, serum SP-D levels in the
positive group were significantly lower than in the negative
group and remained consistently low during the course of
treatment. In the negative group, serum SP-D levels
decreased after anti-inflammatory treatment in most of the
cases. Several studies have reported that serum SP-D
concentrations are correlated with the extent of alveolitis
(most commonly reflected by increased cellularity in the
alveolar interstitium), but not with the progression of fibro-
sis [19]. Thus, low serum SP-D levels in the positive group
may reflect poor cellularity and progressive fibrotic change,
whereas high serum SP-D levels in the negative group may
reflect relatively abundant cellularity.
As a background to the differences in the KL-6 and
SP-D levels, we believe that immune reactions may differ
in the lung between the two groups. The following two
results support this supposition. 1) Serum levels of AST
and γ-GTP were significantly higher in the positive
group than in the negative group. Elevation of serum hepa-
tobiliary enzymes was reported to be correlated with ILD in
anti-MDA-5 antibody positive DM and CADM patients
[20–22]. It was supposed that anti-MDA-5 antibody is asso-
ciated with alveolar macrophage activation, thereby causing
injury not only to the skin and lung, but also to the liver. 2)
Furthermore, the CD4+/CD8+ ratio in the BAL fluid was
significantly higher in the positive group than in the nega-
tive group. No previous reports have compared the results
of BAL analysis between anti-MDA-5 antibody-positive
and anti-MDA-5 antibody-negative CADM-ILD patients.
Although it remains controversial whether the BAL
lymphocyte subset is useful for clinical diagnosis of ILD,
Suda et al. reported a higher CD4+/CD8+ ratio in patients
with acute/subacute CADM-ILD than chronic CADM-
ILD [23]. Mukae et al. also showed a higher CD4+/CD8+
ratio in the BAL fluid of CADM patients than in those
with classic DM [5]. In addition, Ito et al. found a higher
CD4+/CD8+ ratio in the BAL fluid of DM patients with
RP-ILD than DM patients with chronic ILD [24]. These
results provide further confirmation of our data.
As well as laboratory data, radiological findings were
quite different between the two groups. In the present
study, the most common HRCT pattern in the positive
group was lower subpleural GGO followed by subpleural
irregular linear opacity. Although no previous reports have
clarified HRCT findings of anti-MDA-5 antibody-positive
CADM-ILD, Tanizawa et al. reported that the most
common HRCT pattern in anti-MDA-5 antibody-positive
DM-ILD is lower GGO/consolidation (50 %) followed by
random GGO (33 %) [22]. Irregular linear opacities were
also reported to be typical in CADM-ILD [13, 23, 25]. Intri-
guingly, the prevalence of GGO was significantly higher in
Table 3 Comparison of HRCT findings between patients with and without anti-CADM-antibody
MDA-5 positive MDA-5 negative p value
(n = 10) (n = 6)
Distribution
Upper lobe dominant 1 (10 %) 0 1.00
Lower lobe dominant 9 (90 %) 6 (100 %) 1.00
Peribronchovascular 2 (20 %) 4 (67 %) 0.118
Subpleural 8 (80 %) 2 (33 %) 0.118
Main findings
Consolidation 1 (10 %) 5 (83 %) 0.00762
Ground glass opacity 5 (50 %) 0 0.0934
Reticulation 1 (10 %) 0 1.00
Irregular linear opacity 3 (30 %) 1 (17 %) 1.00
Additional findings
Traction bronchiectasis 5 (50 %) 4 (67 %) 0.633
Cyst 0 1 (17 %) 0.375
Subpleural curve linear shadow 4 (40 %) 3 (50 %) 1.00
Thickening of interlobular septa 2 (20 %) 2 (33 %) 0.604
Emphysema 1 (10 %) 1 (17 %) 1.00
Volume loss 9 (90 %) 5 (83 %) 1.00
Categorical data are presented as numbers (percentages) and were analyzed using Fisher’s exact test
Abbreviations: CADM clinically amyopathic dermatomyositis, HRCT high-resolution computed tomography, MDA-5, anti-melanoma differentiation-associated gene 5
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non-survivors among anti-MDA-5 antibody-positive cases
in the present study. Moreover, in one anti-MDA-5
antibody-positive case with subpleural GGO (as shown in
Fig. 2a), autopsy revealed diffuse alveolar septal thickening
due to organizing fibrosis, airspace organization, and
hyaline membranes, suggesting a diffuse alveolar damage
(DAD) pattern. Although no reports have evaluated the
histopathological findings of treatment-naïve CADM-ILD
with anti-MDA-5 antibody, the pathological findings of
autopsied lung in CADM-ILD with anti-MDA-5 antibody
mostly revealed a DAD pattern [26–28]. Therefore, GGO
in HRCT of anti-MDA-5 antibody-positive CADM-ILD
Fig. 2 High-resolution computed tomography findings. Representative photographs of HRCT scans are presented. a and b initial HRCT scans of
fatal cases positive for anti-MDA-5 antibody showing subpleural GGO. (C) HRCT scans of an anti-MDA-5 antibody-positive patient who survived,
showing subpleural irregular linear opacity. (D) HRCT scans of an anti-MDA-5 antibody-negative patient showing peribronchovascular consolidation.
Abbreviations: GGO, ground-glass opacity; HRCT, high-resolution computed tomography; MDA-5, anti-melanoma differentiation-associated gene 5
Fig. 3 Comparison of survival curves with and without anti-MDA-5 antibody. Cumulative survival probabilities were estimated using the Kaplan–Meier
method. The log-rank test was used to compare survival among patient groups. A p value of <0.05 was considered statistically significant. Abbreviation:
MDA-5, anti-melanoma differentiation-associated gene 5
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may reflect the histopathology of DAD. On the contrary,
peribronchovascular consolidation, which is suggestive of
nonspecific interstitial pneumonia or organizing pneumo-
nia, was most frequently observed in the negative group.
Such CT patterns are generally observed in ILD with classic
DM; in fact, anti-ARS antibody was detected in 50 % of the
negative cases.
These theories on the correlation between HRCT find-
ings and pathological findings are supported by the
differences in treatment response and prognosis between
the two groups. The anti-MDA-5 antibody-positive cases
had significantly lower survival rates than anti-MDA-5
antibody-negative cases; all six fatal cases were positive
for anti-MDA-5 antibody and died from refractory ILD
despite intensive initial treatment, whereas favorable
treatment response and prognosis were observed in the
negative group.
As described above, there are clear differences in the
clinical features and prognosis between anti-MDA-5
antibody-positive and anti-MDA-5 antibody-negative
CADM-ILD; thus, it would be appropriate to separate
CADM-ILD by the presence or absence of anti-MDA-5
antibody. However, only a few medical facilities can
measure anti-MDA-5 antibody levels, and it takes time
to obtain test results; thus, the anti-MDA-5 antibody is
not very helpful for deciding on a treatment policy and
forecasting prognosis. Low levels of serum KL-6 and
SP-D, high levels of serum AST, γ-GTP, and CD4+/CD8+
ratio in BAL fluid, and the predominance of subpleural
GGO or irregular linear opacity in HRCT may provide
Table 4 Comparisons of characteristics and examination findings between anti-MDA-5-positive survivors and non-survivors
Survivors Non-survivors p
value(n = 4) (n = 6)
Gender (male/female) 2/2 4/2 1.00
Age 58.5 (47.8–64.3) 63.0 (59.3–64.5) 0.519
Time
from onset to first visit 29.5 (26.0–50.3) 11.0 (11.0–13.3) 0.0666
from onset to treatment initiation 68.5 (31.5–107) 16.0 (12.8–23.0) 0.0381
Symptoms and signs
Gottron’s sign 2 (50 %) 5 (83 %) 0.500
Heliotrope eruption 2 (50 %) 5 (83 %) 0.500
V/shawl neck sign 1 (25 %) 4 (67 %) 0.524
Mechanic’s hands 0 2 (33 %) 0.467
Palmar erythema 0 2 (33 %) 0.467
Myalgia 2 (50 %) 1 (17 %) 0.500
Cough 4 (100 %) 1 (17 %) 0.0480
Dyspnea on exertion 3 (75 %) 2 (33 %) 0.524
Fever 3 (75 %) 6 (100 %) 0.200
Laboratory data
Aspartate aminotransferase 55.5 (36.8–76.8) 55.5 (41.0–110) 0.762
γ-glutamyl transpeptidase 53.5 (43.5–57.5) 28.0 (23.0–110) 0.914
Krebs von den Lungen-6 1135 (930–1190) 524 (470–626) 0.114
Surfactant protein D 45.3 (23.7–75.8) 32.5 (24.2–40.9) 0.669
Bronchoalveolar lavage
CD4+/CD8+ ratio 3.52 (2.12–4.04) 1.47 (1.20–2.19) 0.857
HRCT findings
Consolidation 1 (25 %) 0 0.400
Ground glass opacity 0 5 (83 %) 0.0480
Reticulation 1 (25 %) 0 1.00
Irregular linear opacity 2 (50 %) 1 (17 %) 0.500
Categorical data are presented as numbers (percentages) and were analyzed using Fisher’s exact test. Continuous data are presented as medians (interquartile
ranges) and were analyzed using the Mann–Whitney U test. A p value of <0.05 was considered statistically significant
Abbreviations: HRCT high-resolution computed tomography, MDA-5, anti-melanoma differentiation-associated gene 5
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clues for discriminating anti-MDA-5 antibody-positive
CADM-ILD with poor prognosis. On the other hand,
the clinical features of anti-MDA-5 antibody-negative
CADM-ILD appear rather similar to those of classical
DM-ILD, and, thus, should probably not be considered as a
distinct clinical entity from classic DM; continuous moni-
toring of muscle and other clinical symptoms is required.
A limitation of the present study is the retrospective
single-center study design. The number of included
patients was small, and the distribution of patients may
have been skewed. Another important limitation to this
study is the risk of multiple comparison testing. Because of
the high number of statistical tests in spite of small number
of the patients, some of these will yield a p-value of <0.05
by chance alone. As for ILD associated with CADM, there
are regional and racial differences in the prevalence of ILD
and the ratio of RP-ILD to the total population of
CADM-ILD [1–4]. Additionally, the prevalence of
anti-MDA-5 antibody is reportedly higher in Eastern Asia
than in Europe or the US, although no previous studies
have made direct comparisons [20, 21, 24, 29–31].
Conclusions
Anti-MDA-5 antibody-positive and anti-MDA-5 antibody-
negative CADM-ILD have clearly different clinico-
radiological features and prognosis, and, thus, it would
be appropriate to separate CADM-ILD by the presence
or absence of anti-MDA-5 antibody. Further investigation
with more cases is required to identify factors associated
with poor prognosis among anti-MDA-5 antibody-positive
CADM-ILD cases.
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